Organon & Co.
Organon & Co. (NYSE: OGN) is a worldwide healthcare firm that develops and markets novel health solutions for women's health, biosimilars, and existing brands. OGN has six production facilities in Belgium, Brazil, Indonesia, Mexico, Netherlands, and United Kingdom.
Why should Investors Sell?
Valuation Methodology: Price/Earnings Multiple Based Relative Valuation
(Source: Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
The company has reported a significant fall in its fundaments. OGN's share price has risen 6.90% in the past month and is currently leaning towards the higher band of its 52-week range of USD 27.25 to USD 38.75. Based on a decline in fundamentals, weak margins, leveraged balance sheet, current valuation and bearish technical indicators, we recommend a "Sell" rating on the stock at the current price of USD 34.89, up 1.19% as of February 11, 2022, at 2:01 PM ET.
Three-Year Technical Price Chart (as of February 11, 2022, at 2:01 PM ET). Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.